<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00196846</url>
  </required_header>
  <id_info>
    <org_study_id>GBG37</org_study_id>
    <secondary_id>Eudract Number: 2004-003980-62</secondary_id>
    <nct_id>NCT00196846</nct_id>
  </id_info>
  <brief_title>Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO)</brief_title>
  <official_title>Prospective Randomized Multicenter Study to Prevent Chemotherapy Induced Ovarian Failure With the GnRH-Agonist Goserelin in Young Hormone Insensitive Breast Cancer Patients Receiving Anthracycline Containing (Neo-)Adjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Breast Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German Breast Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study done in young breast cancer patients to prevent chemotherapy induced ovarian failure&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:&#xD;
&#xD;
      Prospective, randomized, open phase II trial&#xD;
&#xD;
      Schedule:&#xD;
&#xD;
      All patients will receive an anthracycline-containing polychemotherapy.&#xD;
&#xD;
      Patients randomized to Goserelin will receive their first injection of 3.6 mg at least 2&#xD;
      weeks before start of chemotherapy. Goserelin will be given as a subcutaneous injection in&#xD;
      the abdominal wall every 4 weeks (28 ± 3 days) until the end of the last chemotherapy cycle.&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      •To increase the percentage of patients with normal ovarian function at 6 months after&#xD;
      application of (neo)adjuvant, anthracycline-containing polychemotherapy in parallel with&#xD;
      Goserelin compared to chemotherapy alone.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      To compare the two treatment groups regarding&#xD;
&#xD;
        -  Compliance to treatment&#xD;
&#xD;
        -  Toxicity&#xD;
&#xD;
        -  Quality of life&#xD;
&#xD;
        -  Menopausal Symptoms Score&#xD;
&#xD;
        -  Ovarian function at 6, 12, 18 and 24 months&#xD;
&#xD;
        -  Duration until recovery of regular menstrual period&#xD;
&#xD;
        -  Pregnancy rate&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normal ovarian function as defined by two consecutive menstrual periods within 21-35 days within a time frame of 5 - 8 months after last application of goserelin</measure>
    <time_frame>December 2008</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Discontinuation, delay, or dose-reductions of chemotherapy</measure>
    <time_frame>December 2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation or delay of Goserelin injections</measure>
    <time_frame>December 2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any grade II to grade IV AE specified to serious or non serious events during treatment with chemotherapy +/- Goserelin</measure>
    <time_frame>December 2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation according to EORTC Q 30</measure>
    <time_frame>March 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>According to menopausal symptom score: E2, FSH, LH, SHGB, and Progesterone at 0, 6, 12, 18 and 24 months</measure>
    <time_frame>March 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Date of first regular menstrual period</measure>
    <time_frame>March 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any diagnosis of pregnancy during study follow up</measure>
    <time_frame>March 2010</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent must be obtained and documented according to the local&#xD;
             regulatory requirements prior to beginning specific protocol procedures&#xD;
&#xD;
          -  Complete baseline documentation sent to GBG&#xD;
&#xD;
          -  Age of at least 18 and at most 45 years&#xD;
&#xD;
          -  Patients request to preserve ovarian function&#xD;
&#xD;
          -  Spontaneous and regular menstrual periods before study entry with FSH below 15 mlU/ml&#xD;
             in follicular phase&#xD;
&#xD;
          -  Histologically confirmed primary breast cancer with the need for anthracycline-based&#xD;
             chemotherapy&#xD;
&#xD;
          -  Steroid receptor (estrogen and progesterone) negative tumor (diagnosis according to&#xD;
             hospital standard-procedures)&#xD;
&#xD;
          -  No clinical evidence of local recurrence or distant metastases. Complete staging&#xD;
             work-up within 3 months prior to registration. All patients must have (bilateral)&#xD;
             mammography or breast MRI, chest X-ray; other tests may be performed as clinically&#xD;
             indicated&#xD;
&#xD;
          -  Karnofsky-Index &gt;80%&#xD;
&#xD;
          -  Life expectancy of at least 10 years, disregarding the diagnosis of cancer&#xD;
&#xD;
          -  Adequate organ function including normal red and white blood count, platelets, serum&#xD;
             creatinine, bilirubin, and transaminases within normal range of the institution&#xD;
&#xD;
          -  Patients must be available for and compliant to treatment and follow-up. Patients&#xD;
             registered on this trial must be treated and followed up at the participating center.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity reaction to the investigational compounds or incorporated&#xD;
             substances&#xD;
&#xD;
          -  Prior cytotoxic treatment for any reason&#xD;
&#xD;
          -  Suspected (primary or secondary) ovarian insufficiency&#xD;
&#xD;
          -  Pregnant or lactating patients. Patients of childbearing potential must have a&#xD;
             negative pregnancy test (urine or serum) within 14 days prior to registration and must&#xD;
             implement adequate non-hormonal contraceptive measures during study treatment; prior&#xD;
             use of hormonal contraceptives has to be discontinued before first Goserelin injection&#xD;
&#xD;
          -  Other serious illness or medical condition that may interfere with the understanding&#xD;
             and giving of informed consent and the conduct of the study&#xD;
&#xD;
          -  Prior or concomitant secondary malignancy (except non-melanomatous skin cancer or&#xD;
             carcinoma in situ of the uterine cervix)&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs or any other anti-cancer therapy&#xD;
&#xD;
          -  Concurrent treatment with sex hormones. Prior treatment must be stopped before study&#xD;
             entry&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernd Gerber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rostock Universität, Universitätsfrauenklinik</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsfrauenklinik, Rostock Universität</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg Vorpommern</state>
        <zip>18075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.germanbreastgroup.de</url>
    <description>Click here for more information about this study: ZORO Study</description>
  </link>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>June 11, 2010</last_update_submitted>
  <last_update_submitted_qc>June 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Konstantin Reißmüller</name_title>
    <organization>GBG</organization>
  </responsible_party>
  <keyword>hormone insensitive breast cancer</keyword>
  <keyword>Prevention of Chemotherapy induced ovarian failure</keyword>
  <keyword>P.O.F.</keyword>
  <keyword>GnRH-Agonist Goserelin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

